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ABSTRACT
Aims To assess the functional and morphological
outcome of eyes with neovascular AMD treated with
intravitreal ranbizumab following an exit strategy
treatment regime.
Methods The Bern treatment regime for neovascular
AMD has a ﬁxed injection schedule, even in the non-
active stage of the disease. The regimen has been
adapted from the PIER study treatment protocol. Eyes
with non-active AMD will receive 4 injections in the ﬁrst
year, and 2 injections in the second year of follow-up
before treatment stops. Patients that received
ranibizumab for treatment and reached the exit criteria
were identiﬁed, and charts were reviewed to assess
functional and morphological outcome.
Results Only 2.6% of all patients (15 out of 575
patients) reached the exit criteria. Mean change in best
corrected ETDRS visual acuity (VA) was 4.5±16.9 letters
when comparing baseline VA to 4 weeks after the last
injection (p=0.32). OCT mean foveal thickness was
signiﬁcantly thinner after last treatment (247.9
±43.0 mm) compared to baseline (332.5±83.1 mm,
p=0.002). The mean total number of ranibizumab
injections was 15.6±8.0, and the mean total treatment
period was 40.9±18.3 months. Twenty percent of eyes
had geographic atrophy present at baseline versus
46.6% at the end of treatment.
Conclusions Even with a ﬁxed treatment regime and a
deﬁned treatment exit strategy, only a small percentage
of patients reach exit criteria. Retinal thickness has been
signiﬁcantly reduced by repeated intravitreal ranibizumab
injections, and geographic atrophy became more
frequent.
INTRODUCTION
Age-related macular degeneration (AMD) is the
leading cause of visual impairment and irreversible
blindness among elderly people over 50 years of age
in the Western world.1 Vascular endothelial growth
factor-A (VEGF-A) has been identiﬁed as the key
factor for the pathogenesis of exudative AMD, which
has the worst prognosis.2 Over the last 10 years, a
number of new antibodies against VEGF-A emerged
for intraocular treatment. Ranibizumab is a recom-
binant, humanised, monoclonal antibody Fab frag-
ment that inhibits all biologically active VEGF-A
isoforms.3 It is indicated in active neovascular AMD
with evidence of intraretinal or subretinal ﬂuid by
optical coherence tomography (OCT), intraretinal
and subretinal haemorrhage, enlargement of chor-
oidal neovascularisation (CNV) size on ﬂuorescence
angiography, and when there is a new or persistent
leakage on ﬂuorescence angiography.4 5
The International Retina Expert panel has recom-
mended an evidence-based guideline to optimise
treatment outcome with ranibizumab in neovascular
AMD.6 This recommendation is based on the evi-
dence available from prospective, multicentre studies
evaluating different ranibizumab treatment schedules,
such as ANCHOR,7 MARINA,8 PIER,9 SAILOR,10
SUSTAIN11 and EXCITE.12 In clinical routine, many
different treatment regimes for ranibizumab are avail-
able (for example: monthly injections, PRN, treat
and extend). Although criteria are relatively clear
regarding when to start antiVEGF treatment, there is
quite some uncertainty when to stop therapy.
In the Bern treatment regime, patients receive
three monthly injections during the loading phase.
After the loading phase, patients were initially fol-
lowed monthly and treated pro re nata. Patients were
closely followed with OCT, ETDRS visual acuity
testing and fundus biomicroscopy during each
follow-up, and in case of relapse with disease activity,
the regime would start with a reloading phase over
again.13 Every retreatment due to new disease activity
triggered three additional monthly injections. In case
of no disease activity, patients received ﬁxed injec-
tions every 3 months for a period of 1 year. In the
second year without disease activity, two more injec-
tions were performed after 6 months and 12 months,
after the last injection therapy was stopped. Figure 1
shows a scheme of the Bern treatment regime. The
purpose of this study was to identify patients who ﬁn-
ished treatment following the complete Bern treat-
ment regime to assess functional and anatomical
outcome.
PATIENTS AND METHODS
All patients treated with intravitreal antiVEGF drugs
at the Department of Ophthalmology, Inselspital,
University Hospital Bern, Switzerland, are registered
in an institutional database. Local IRB-approved
retrospective analysis of data for this study. Charts of
patients who received intravitreal injections with rani-
bizumab for neovascular AMD were identiﬁed.
Treatment had to be started after 12/2008 to assure
that the Bern treatment regime was applied. All treat-
ments were performed between 12/2008 and 3/
2013. No previous treatment for neovascular AMD
was allowed in this study. Out of 1295 identiﬁed
patients who received ranibizumab for neovascular
AMD, 335 patients had prior treatment with bevaci-
zumab, photodynamic therapy or conventional laser
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treatment. Three hundred and eightyfive patients were switched to
aﬂibercept during therapy. Therefore, 575 patients received ranibi-
zumab as the only treatment for neovascular AMD within that
time period. Out of these patient groups, only 15 patients ﬁnished
treatment following the complete Bern treatment regime (see
ﬁgure 2). Only one eye per patient was considered for inclusion
since none of the 15 patients had bilateral treatment for exudative
AMD. All other patients still needed treatment, or dropped out of
the regime for other reasons. Charts of these 15 patients were
reviewed, and the following data was analysed: Best corrected
ETDRS visual acuity (VA) was tested before the ﬁrst treatment, at
every injection date, and 4 weeks after the last injection. Mean
OCT retinal thickness values of the fovea (ETDRS grid) were
documented before ﬁrst treatment, at every injection date, and
4 weeks after the last injection. Structural retinal changes in OCT
images were assessed before the ﬁrst treatment and 4 weeks after
the last injection. Retinal morphologic changes, such as subretinal
haemorrhages, pigment epithelium detachments, intraretinal and/
or subretinal ﬂuid, geographic atrophy, and ﬁbrovascular scar for-
mation were documented if seen during fundus biomicroscopy or
on fundus photographs before treatment and 4 weeks after the last
injection. Additionally, ﬂuorescein angiography ﬁndings before the
ﬁrst treatment were assessed. Follow-up ﬂuorescein angiography
was performed every 6–12 months or at the discretion of the treat-
ing physician. Additionally, indocyanin green angiography was per-
formed occasionally if required.
Active CNV was deﬁned as loss of ≥5 letters on the ETDRS
chart (not due to scar formation or atrophy), abnormal OCT
retinal thickness with signs of intraretinal or subretinal ﬂuid, or
new retinal haemorrhage.
Data was analysed using Prism 5 (V.5.02, Graphpad Software,
7825 Fay Avenue, Suite 230, La Jolla, California 92037 USA).
Student paired t test was used to compare VA and OCT thick-
ness values before and after treatment. Pairwise correlation was
performed using Spearman’s coefﬁcient correlation to assess
correlation between total number of injections and VA gain, and
between total number of injections and change in foveal thick-
ness; p<0.05 were considered statistically signiﬁcant.
RESULTS
Fifteen eyes of 15 patients (10 women) with a mean age of 81
±9.9 years (mean±SD) were included. No patients had any
prior antiVEGF therapy for neovascular AMD. Mean ETDRS
VA prior to therapy was 55±15.4 letters. Mean ETDRS VA at
the end of therapy was 59.6±17.6 letters. Mean change in VA
was 4.5±16.9 letters which was not statistically signiﬁcant
(p=0.3). Mean foveal thickness was signiﬁcantly thinner after
last treatment (247.9±43.0 mm) compared to baseline (332.5
±83.1 mm, p<0.002). Mean change in foveal retinal thickness
was -78.9±94.1 mm. The mean total number of ranibizumab
injections was 15.6±8.0 (min.: 9; max.: 39 injections) and the
mean total treatment period was 40.9±18.3 months (min.: 27;
max.: 86 months). VA gain and number of injections were posi-
tively correlated (p=0.046, Rsquare=0.27). No signiﬁcant correl-
ation was found for the number of injections and mean foveal
thickness (p=0.2, Rsquare=0.12) change. Fluorescein angiog-
raphy prior to treatment revealed 12 cases (80%) of occult chor-
oidal neovascularisation (CNV) and 3 cases (20%) of classic
CNV. Table 1 shows additional morphologic characteristics prior
to treatment and at the end of therapy.
DISCUSSION
Although the introduction of antiVEGF therapy for neovascular
AMD led to a big improvement in VA compared to the natural
course of the disease, there is an ongoing controversy regarding
the best treatment regime and tapering treatment. Currently,
antiVEGF drugs cannot cure the disease, but at least in the
initial stages of therapy, could lead to an improvement in visual
acuity. The Bern treatment regime is relatively strict with at least
six intravitreal injections of ranibizumab within the ﬁrst
12 months even if the disease never becomes active again after
the loading phase. Even in the optimal course without disease
recurrence, patients will receive at least nine injections during
the whole treatment regime (see ﬁgure 1). The Bern treatment
regime offers a precise exit strategy in contrast with many other
regimes such as the treat-and-extend, or PRN scheme. To our
Figure 1 Scheme of the Bern
treatment regime to treat neovascular
AMD with intravitreal ranibizumab
injections. Active disease is treated
with at least 3 monthly injections
(loading phase). Non-active disease is
treated with injections every three
months during the ﬁrst year and every
six months during the second year. If
the disease remains non-active over
24 months, the therapy ends. Any
recurrence of disease activity will lead
to a new loading phase, and the
regime starts over again.
Figure 2 Graph indicating the
numbers and reasons for inclusion or
exclusion of patients.
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knowledge, this might be the ﬁrst study reporting the outcome
of patients that met the exit criteria of a ﬁxed treatment
regimen for exudative AMD. Literature search in pubmed found
no relevant data in this matter. However, it was very surprising
how few patients actually ﬁnished the treatment. Only 2.6% off
all patients in our database ﬁnished treatment and reached the
exit criteria. Most patients seemed to drop out due to other
reasons, or needed continuous treatment. There are many
reasons for a patient not to reach the last stages of the mainten-
ance treatment, such as ﬁbrovascular scar formation, very low
VA, or decision of the patient not to ﬁnish the treatment.
Interestingly, 5 out of 15 patients (33.3%) only required the
minimum nine injections to exit the regime. One can even
hypothesise, that the fraction of 15 patients that actually made
it to the end of the treatment regime are generally good respon-
ders to ranibizumab treatment, compared to all other patients
that never met the exit criteria.
Fundus biomicroscopy and OCT revealed subretinal ﬂuid in
60% of all patients prior to therapy. Additionally, 60% of
patients showed intraretinal ﬂuid at baseline. All patients had
either subretinal or intraretinal ﬂuid, or both, at baseline. No
patient showed remaining subretinal ﬂuid, and only one patient
had some remaining intraretinal ﬂuid at the end of therapy. By
contrast, no change was found in the rate of pigment epithelium
detachment (13.3%). Only two eyes (13.3%) developed new
ﬁbrotic scar tissue within the macula area despite antiVEGF
therapy. Interestingly, the rate of geographic atrophy increased
from three cases (20%) prior therapy to seven cases (46.6%)
after therapy. This increase might be associated with intravitreal
ranibizumab treatment. Recently, Grunwald JE et al published
work describing risk factors for the development of geographic
atrophy in the Comparison of Age-related macular degeneration
Treatment Trials (CATT). They analysed 1024 CATT patients14
with no geographic atrophy visible at enrolment, and followed
patients during 1 year of monthly injections and 1 year of PRN
treatment with antiVEGF drugs (ranibizumab or bevacizumab).
Approximately one-ﬁfth of CATT patients developed geographic
atrophy within 2 years of treatment, and authors concluded that
antiVEGF treatment may play a role in the development of geo-
graphic atrophy.
In our study group, overall VA gain was 4.5±16.9 letters
compared to baseline, with a mean follow-up of 40.9
±18.3 months. These ﬁndings are comparable with the results
of various major studies which reported general stabilisation
and/or improvement of VA after intravitreal ranibizumab.4 7–12
Recently, a multicentre cohort study (SEVEN-UP) was pub-
lished showing the seven-year outcome of eyes treated with rani-
bizumab in ANCHOR, MARINA and HORIZON.15 At a mean
of 7.3 years (range, 6.3–8.5 years) after entry into ANCHOR or
MARINA, 37% of study eyes met the primary end point of 20/
70 or better VA, with 23% achieving a VA of 20/40 or better.
Thirty-seven percent of study eyes had VA of 20/200 or worse.
Forty-three percent of study eyes had a stable or improved letter
score (≥0-letter gain) compared with ANCHOR or MARINA
baseline measurements, whereas 34% declined by 15 letters or
more, with an overall mean decline of 8.6 letters (p<0.005).
The study showed that even after 7 years of extensive treatment,
neovascular AMD remains a risk for substantial visual loss. Only
one-third of patients had good visual outcome, half the patients
remained stable, but one-third declined by 15 letters or more
despite regular therapy.
Our data underlines the fact that antiVEGF treatment for
neovascular AMD is useful and effective in preserving vision in
many, but not all patients. There is still no cure for neovascular
AMD, and antiVEGF treatment confronts the physician with a
number of unsolved problems, such as unknown long-term side
effects (ie, geographic atrophy), and lack of alternative treatment
options or exit strategies.
There are certain limitations of this study. First, the sample
size of patients that met exit criteria is small. Therefore, the
outcome of patients might not be representative. The functional
and anatomical outcome of all patients who did not meet exit
criteria would have been interesting as well, since we do not
know why these patients did not respond well enough to treat-
ment. However, that data could not be analysed in this study.
Additionally, there is no control group (that would have been
treated with another exit strategy) for comparison. Therefore,
we do not know if our applied exit strategy is effective and safe
in deﬁning end of treatment. Long-term follow-up of these 15
patients would be needed to calculate the recurrence rate after
end of therapy over the next couple of years.
In conclusion, our study showed that even with a ﬁxed treat-
ment regime and a deﬁned treatment exit strategy, only a small
percentage of patients will actually complete the exit phase.
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